Laimai Pharmaceuticals: Some of the company's products are selected for national centralized procurement and will continue to be purchased

K-LinePoet · 2026-03-09T18:29:18+00:00

Limei Pharmaceutical Announcement: The continuation procurement bidding for the national organized centralized procurement drugs participated by the company and its wholly-owned subsidiary Hunan Kangyuan Pharmaceutical Co., Ltd. has been completed, and some products are proposed to be selected for this continuation procurement. In 2024, the sales revenue of the proposed selected products is expected to be 106 million yuan, accounting for 13.35% of the company's operating income for 2024; in the first three quarters of 2025, the sales revenue is 66.0742 million yuan, accounting for 11.37% of the company's operating income for the first three quarters of 2025.

K-LinePoet

2026-03-09 18:29:18

Lamei Pharmaceutical announces that the continuation procurement bidding for drugs participated in by the company and its wholly owned subsidiary, Hunan Kangyuan Pharmaceutical Co., Ltd., has been completed, with some products selected for this continuation procurement. In 2024, the projected sales revenue of the selected products is 106 million yuan, accounting for 13.35% of the company’s total revenue for 2024; in the first three quarters of 2025, the sales revenue is 66.0742 million yuan, accounting for 11.37% of the company’s revenue for the same period.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes